Appropriateness of Hemostatic Agent Use in Cardiovascular Surgery (HAEMOVAX)

Hemostatic agents are widely used in cardiac and vascular surgery to support intraoperative bleeding control. Despite their clinical relevance and substantial economic impact, little is known about real-world patterns of use, adherence to evidence-based recommendations, and the alignment between clinicians' perceived knowledge and actual decision-making. HAEMOVAX is a single-center mixed-methods observational study conducted at IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy. The study combines an anonymous survey of cardiovascular surgeons with a retrospective audit of institutional hemostatic agent consumption. The primary objective is to evaluate the appropriateness of hemostatic agent selection using a Knowledge-Practice Alignment Score (KPA-Score) derived from standardized clinical vignettes based on current EACTS and ESA recommendations. Secondary objectives include assessment of usage patterns, barriers to appropriate use, concordance between declared practice and real-world consumption, and opportunities for evidence-based standardization.

NCT Number	NCT07699016
Lead Sponsor	University of Milan
Conditions	Hemostasis, Perioperative Bleeding, Cardiovascular Surgery, Cardiac Surgery, Vascular Surgery
Enrollment	15 participants
Start Date	2026-07-01
Primary Completion	2026-07-16 (estimated)
Study Completion	2026-08-15 (estimated)
Updated on ClinicalTrials.gov	2026-07-13